AKSIGEN Hospital Care is a niche, research driven Healthcare Company dedicated to putting patients well being first. The Company founded in 1994, was incorporated with a mission of introducing pathbreaking therapies in the anti-inflammatory space.With this, Aksigen became the pioneer of the systemic enzyme therapy segment in India- Aksigen was the first Indian company to launch the safe and effective combination of the Trypsin, Bromelain & Rutoside in India. The company continued its pathbreaking journey by launching the first and only dispersible formulation of TBR in the world.With the patient safety being the primary objective, Aksigen is the first Indian company to get the DCGI approval for the combination of TBR by conducting a large clinical trial in 300 Plus patient to establish the safety and efficacy of the drug. The company further expanded its portfolio to provide wholistic treatment for management of Bone and Joint Disorder. With a track record of innovation and being pioneers in the segment, Aksigen continues to strive to empower the medical fraternity with research driven clinically proven products to ensure desired healthcare outcomes.